127 related articles for article (PubMed ID: 25301960)
1. A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.
Kiesgen S; Liebers N; Cremer M; Arnold U; Weber T; Keller A; Herold-Mende C; Dyckhoff G; Jäger D; Kontermann RE; Arndt MA; Krauss J
Protein Eng Des Sel; 2014 Oct; 27(10):331-7. PubMed ID: 25301960
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
3. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
Kiesgen S; Arndt MAE; Körber C; Arnold U; Weber T; Halama N; Keller A; Bötticher B; Schlegelmilch A; Liebers N; Cremer M; Herold-Mende C; Dyckhoff G; Federspil PA; Jensen AD; Jäger D; Kontermann RE; Mier W; Krauss J
Cancer Lett; 2015 Feb; 357(1):364-373. PubMed ID: 25434798
[TBL] [Abstract][Full Text] [Related]
4. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli.
Ma C; Li Y; Li Z; Huang H; Xu K; Xu H; Bai J; Li X; Zhao G
Protein Expr Purif; 2012 May; 83(1):1-7. PubMed ID: 22381467
[TBL] [Abstract][Full Text] [Related]
7. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
8. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
9. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
[TBL] [Abstract][Full Text] [Related]
10. Endosomal escape efficiency of fusogenic B18 and B55 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation.
Niikura K; Horisawa K; Doi N
J Biochem; 2016 Jan; 159(1):123-32. PubMed ID: 26338729
[TBL] [Abstract][Full Text] [Related]
11. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
De Lorenzo C; Nigro A; Piccoli R; D'Alessio G
FEBS Lett; 2002 Apr; 516(1-3):208-12. PubMed ID: 11959134
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
[TBL] [Abstract][Full Text] [Related]
13. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
14. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.
Goyal A; Batra JK
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):247-54. PubMed ID: 10620501
[TBL] [Abstract][Full Text] [Related]
15. Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display human scFv against EGFR.
Zhou Y; Zhang J; Jin H; Chen Z; Wu Q; Li W; Yue M; Luo C; Wang M
Biomed Pharmacother; 2013 Oct; 67(8):737-43. PubMed ID: 23639232
[TBL] [Abstract][Full Text] [Related]
16. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
17. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.
Hussain AF; Kampmeier F; von Felbert V; Merk HF; Tur MK; Barth S
Bioconjug Chem; 2011 Dec; 22(12):2487-95. PubMed ID: 21995499
[TBL] [Abstract][Full Text] [Related]
18. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
19. Soluble Expression in Escherichia coli of a Single-Domain Antibody-Tumor Necrosis Factor α Fusion Protein Specific for Epidermal Growth Factor Receptor.
Osaki T; Nakanishi T; Aoki M; Omizu T; Nishiura D; Kitamura M
Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):20-25. PubMed ID: 29474158
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy.
Cao X; Yu H; Chen C; Wei J; Wang P
Biotechnol Lett; 2015 Jul; 37(7):1347-54. PubMed ID: 25735855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
